Neuroprotective  ||| S:0 E:16 ||| JJ
effect  ||| S:16 E:23 ||| NN
of  ||| S:23 E:26 ||| IN
buyang  ||| S:26 E:33 ||| JJ
huanwu  ||| S:33 E:40 ||| JJ
decoction  ||| S:40 E:50 ||| NN
on  ||| S:50 E:53 ||| IN
rat  ||| S:53 E:57 ||| FW
ischemic ||| S:57 E:65 ||| FW
/ ||| S:65 E:66 ||| FW
reperfusion  ||| S:66 E:78 ||| FW
brain  ||| S:78 E:84 ||| NN
damage  ||| S:84 E:91 ||| NN
by  ||| S:91 E:94 ||| IN
promoting  ||| S:94 E:104 ||| VBG
migration  ||| S:104 E:114 ||| NN
of  ||| S:114 E:117 ||| IN
neural  ||| S:117 E:124 ||| JJ
precursor  ||| S:124 E:134 ||| NN
cells  ||| S:134 E:140 ||| NNS
Buyang  ||| S:140 E:147 ||| NNP
Huanwu  ||| S:147 E:154 ||| NNP
Decoction  ||| S:154 E:164 ||| NNP
( ||| S:164 E:165 ||| -LRB-
BYHWD ||| S:165 E:170 ||| NNP
)  ||| S:170 E:172 ||| -RRB-
is  ||| S:172 E:175 ||| VBZ
a  ||| S:175 E:177 ||| DT
classic  ||| S:177 E:185 ||| JJ
formula  ||| S:185 E:193 ||| NN
widely  ||| S:193 E:200 ||| RB
used  ||| S:200 E:205 ||| VBN
for  ||| S:205 E:209 ||| IN
treating  ||| S:209 E:218 ||| VBG
stroke-induced  ||| S:218 E:233 ||| JJ
disability ||| S:233 E:243 ||| NN
,  ||| S:243 E:245 ||| ,
the  ||| S:245 E:249 ||| DT
highest  ||| S:249 E:257 ||| JJS
morbidity  ||| S:257 E:267 ||| NN
of  ||| S:267 E:270 ||| IN
neurological  ||| S:270 E:283 ||| JJ
disorders  ||| S:283 E:293 ||| NNS
in  ||| S:293 E:296 ||| IN
China ||| S:296 E:301 ||| NNP
.  ||| S:301 E:303 ||| .
However ||| S:303 E:310 ||| RB
,  ||| S:310 E:312 ||| ,
the  ||| S:312 E:316 ||| DT
mechanism  ||| S:316 E:326 ||| NN
of  ||| S:326 E:329 ||| IN
its  ||| S:329 E:333 ||| PRP$
neuroprotection  ||| S:333 E:349 ||| NN
has  ||| S:349 E:353 ||| VBZ
not  ||| S:353 E:357 ||| RB
been  ||| S:357 E:362 ||| VBN
fully  ||| S:362 E:368 ||| RB
clarified ||| S:368 E:377 ||| VBN
.  ||| S:377 E:379 ||| .
Previous  ||| S:379 E:388 ||| JJ
reports  ||| S:388 E:396 ||| NNS
indicated  ||| S:396 E:406 ||| VBD
that  ||| S:406 E:411 ||| IN
BYHWD  ||| S:411 E:417 ||| NNP
may  ||| S:417 E:421 ||| MD
promote  ||| S:421 E:429 ||| VB
growth  ||| S:429 E:436 ||| NN
and  ||| S:436 E:440 ||| CC
differentiation  ||| S:440 E:456 ||| NN
of  ||| S:456 E:459 ||| IN
neural  ||| S:459 E:466 ||| JJ
precursor  ||| S:466 E:476 ||| NN
cells  ||| S:476 E:482 ||| NNS
( ||| S:482 E:483 ||| -LRB-
NPCs ||| S:483 E:487 ||| NNP
) ||| S:487 E:488 ||| -RRB-
.  ||| S:488 E:490 ||| .
The  ||| S:490 E:494 ||| DT
present  ||| S:494 E:502 ||| JJ
study  ||| S:502 E:508 ||| NN
focused  ||| S:508 E:516 ||| VBN
on  ||| S:516 E:519 ||| IN
the  ||| S:519 E:523 ||| DT
effects  ||| S:523 E:531 ||| NNS
of  ||| S:531 E:534 ||| IN
BYHWD  ||| S:534 E:540 ||| NNP
on  ||| S:540 E:543 ||| IN
migration  ||| S:543 E:553 ||| NN
of  ||| S:553 E:556 ||| IN
NPCs  ||| S:556 E:561 ||| JJ
in  ||| S:561 E:564 ||| IN
rats  ||| S:564 E:569 ||| NNS
with  ||| S:569 E:574 ||| IN
middle  ||| S:574 E:581 ||| JJ
cerebral  ||| S:581 E:590 ||| JJ
artery  ||| S:590 E:597 ||| NN
occlusion  ||| S:597 E:607 ||| NNS
( ||| S:607 E:608 ||| -LRB-
MCAO ||| S:608 E:612 ||| NNP
) ||| S:612 E:613 ||| -RRB-
.  ||| S:613 E:615 ||| .
Rats  ||| S:615 E:620 ||| NNS
were  ||| S:620 E:625 ||| VBD
treated  ||| S:625 E:633 ||| VBN
with  ||| S:633 E:638 ||| IN
different  ||| S:638 E:648 ||| JJ
doses  ||| S:648 E:654 ||| NNS
of  ||| S:654 E:657 ||| IN
BYHWD  ||| S:657 E:663 ||| NNP
( ||| S:663 E:664 ||| -LRB-
12  ||| S:664 E:667 ||| CD
and  ||| S:667 E:671 ||| CC
24  ||| S:671 E:674 ||| CD
grams ||| S:674 E:679 ||| CD
/ ||| S:679 E:680 ||| CD
kg ||| S:680 E:682 ||| CD
)  ||| S:682 E:684 ||| -RRB-
from  ||| S:684 E:689 ||| IN
day  ||| S:689 E:693 ||| NN
1  ||| S:693 E:695 ||| CD
to  ||| S:695 E:698 ||| TO
day  ||| S:698 E:702 ||| NN
21  ||| S:702 E:705 ||| CD
after  ||| S:705 E:711 ||| IN
model  ||| S:711 E:717 ||| NN
building ||| S:717 E:725 ||| NN
.  ||| S:725 E:727 ||| .
BYHWD  ||| S:727 E:733 ||| NNP
could  ||| S:733 E:739 ||| MD
increase  ||| S:739 E:748 ||| VB
the  ||| S:748 E:752 ||| DT
survival  ||| S:752 E:761 ||| NN
rate  ||| S:761 E:766 ||| NN
and  ||| S:766 E:770 ||| CC
decrease  ||| S:770 E:779 ||| VB
neurological  ||| S:779 E:792 ||| JJ
scores  ||| S:792 E:799 ||| NNS
and  ||| S:799 E:803 ||| CC
infarct  ||| S:803 E:811 ||| JJ
volume  ||| S:811 E:818 ||| NN
as  ||| S:818 E:821 ||| IN
compared  ||| S:821 E:830 ||| VBN
with  ||| S:830 E:835 ||| IN
the  ||| S:835 E:839 ||| DT
vehicle-treated  ||| S:839 E:855 ||| JJ
MCAO  ||| S:855 E:860 ||| NN
rats ||| S:860 E:864 ||| NNS
.  ||| S:864 E:866 ||| .
Moreover ||| S:866 E:874 ||| RB
,  ||| S:874 E:876 ||| ,
BYHWD  ||| S:876 E:882 ||| NNP
treatment  ||| S:882 E:892 ||| NN
significantly  ||| S:892 E:906 ||| RB
increased  ||| S:906 E:916 ||| VBD
5-bromo-2-deoxyuridine  ||| S:916 E:939 ||| CD
( ||| S:939 E:940 ||| -LRB-
BrdU ||| S:940 E:944 ||| NNP
) ||| S:944 E:945 ||| -RRB-
-positive  ||| S:945 E:955 ||| JJ
cells  ||| S:955 E:961 ||| NNS
in  ||| S:961 E:964 ||| IN
the  ||| S:964 E:968 ||| DT
subventricular  ||| S:968 E:983 ||| JJ
zone  ||| S:983 E:988 ||| NN
( ||| S:988 E:989 ||| -LRB-
SVZ ||| S:989 E:992 ||| NNP
) ||| S:992 E:993 ||| -RRB-
,  ||| S:993 E:995 ||| ,
subgranular  ||| S:995 E:1007 ||| JJ
zone  ||| S:1007 E:1012 ||| NN
( ||| S:1012 E:1013 ||| -LRB-
SGZ ||| S:1013 E:1016 ||| NNP
) ||| S:1016 E:1017 ||| -RRB-
,  ||| S:1017 E:1019 ||| ,
and  ||| S:1019 E:1023 ||| CC
corpus  ||| S:1023 E:1030 ||| JJ
striatum  ||| S:1030 E:1039 ||| NNS
( ||| S:1039 E:1040 ||| -LRB-
CS ||| S:1040 E:1042 ||| NNP
)  ||| S:1042 E:1044 ||| -RRB-
of  ||| S:1044 E:1047 ||| IN
the  ||| S:1047 E:1051 ||| DT
infarct  ||| S:1051 E:1059 ||| JJ
brain ||| S:1059 E:1064 ||| NN
.  ||| S:1064 E:1066 ||| .
Interestingly ||| S:1066 E:1079 ||| RB
,  ||| S:1079 E:1081 ||| ,
BYHWD  ||| S:1081 E:1087 ||| NNP
could  ||| S:1087 E:1093 ||| MD
markedly  ||| S:1093 E:1102 ||| RB
enhance  ||| S:1102 E:1110 ||| VB
BrdU ||| S:1110 E:1114 ||| JJ
( ||| S:1114 E:1115 ||| -LRB-
+ ||| S:1115 E:1116 ||| NNP
) ||| S:1116 E:1117 ||| -RRB-
/ ||| S:1117 E:1118 ||| FW
doublecortin ||| S:1118 E:1130 ||| FW
( ||| S:1130 E:1131 ||| -LRB-
+ ||| S:1131 E:1132 ||| NNP
)  ||| S:1132 E:1134 ||| -RRB-
cells  ||| S:1134 E:1140 ||| NNS
not  ||| S:1140 E:1144 ||| RB
only  ||| S:1144 E:1149 ||| RB
in  ||| S:1149 E:1152 ||| IN
the  ||| S:1152 E:1156 ||| DT
SVZ  ||| S:1156 E:1160 ||| NNP
and  ||| S:1160 E:1164 ||| CC
SGZ  ||| S:1164 E:1168 ||| NNP
but  ||| S:1168 E:1172 ||| CC
also  ||| S:1172 E:1177 ||| RB
in  ||| S:1177 E:1180 ||| IN
CS ||| S:1180 E:1182 ||| NNP
,  ||| S:1182 E:1184 ||| ,
by  ||| S:1184 E:1187 ||| IN
up-regulating  ||| S:1187 E:1201 ||| JJ
the  ||| S:1201 E:1205 ||| DT
protein  ||| S:1205 E:1213 ||| NN
expression  ||| S:1213 E:1224 ||| NN
of  ||| S:1224 E:1227 ||| IN
migration  ||| S:1227 E:1237 ||| JJ
activators ||| S:1237 E:1247 ||| NN
,  ||| S:1247 E:1249 ||| ,
including  ||| S:1249 E:1259 ||| VBG
stromal  ||| S:1259 E:1267 ||| JJ
cell  ||| S:1267 E:1272 ||| NN
derived  ||| S:1272 E:1280 ||| VBD
factor-1 ||| S:1280 E:1288 ||| CD
,  ||| S:1288 E:1290 ||| ,
CXC  ||| S:1290 E:1294 ||| NNP
chemokine  ||| S:1294 E:1304 ||| VBD
receptor  ||| S:1304 E:1313 ||| CD
4 ||| S:1313 E:1314 ||| CD
,  ||| S:1314 E:1316 ||| ,
vascular  ||| S:1316 E:1325 ||| JJ
endothelial  ||| S:1325 E:1337 ||| JJ
growth  ||| S:1337 E:1344 ||| NN
factor ||| S:1344 E:1350 ||| NN
,  ||| S:1350 E:1352 ||| ,
Reelin ||| S:1352 E:1358 ||| NNP
,  ||| S:1358 E:1360 ||| ,
and  ||| S:1360 E:1364 ||| CC
brain-derived  ||| S:1364 E:1378 ||| JJ
neurotrophic  ||| S:1378 E:1391 ||| JJ
factor  ||| S:1391 E:1398 ||| NN
in  ||| S:1398 E:1401 ||| IN
the  ||| S:1401 E:1405 ||| DT
ipsilateral  ||| S:1405 E:1417 ||| JJ
infarct  ||| S:1417 E:1425 ||| JJ
area  ||| S:1425 E:1430 ||| NN
after  ||| S:1430 E:1436 ||| IN
MCAO ||| S:1436 E:1440 ||| NNP
.  ||| S:1440 E:1442 ||| .
In  ||| S:1442 E:1445 ||| IN
addition ||| S:1445 E:1453 ||| NN
,  ||| S:1453 E:1455 ||| ,
BYHWD  ||| S:1455 E:1461 ||| NNP
treatment  ||| S:1461 E:1471 ||| NN
was  ||| S:1471 E:1475 ||| VBD
able  ||| S:1475 E:1480 ||| JJ
to  ||| S:1480 E:1483 ||| TO
promote  ||| S:1483 E:1491 ||| VB
the  ||| S:1491 E:1495 ||| DT
neuronal  ||| S:1495 E:1504 ||| JJ
differentiation ||| S:1504 E:1519 ||| NN
,  ||| S:1519 E:1521 ||| ,
which  ||| S:1521 E:1527 ||| WDT
was  ||| S:1527 E:1531 ||| VBD
closely  ||| S:1531 E:1539 ||| RB
related  ||| S:1539 E:1547 ||| VBN
to  ||| S:1547 E:1550 ||| TO
the  ||| S:1550 E:1554 ||| DT
migratory  ||| S:1554 E:1564 ||| JJ
process  ||| S:1564 E:1572 ||| NN
of  ||| S:1572 E:1575 ||| IN
NPCs  ||| S:1575 E:1580 ||| JJ
in  ||| S:1580 E:1583 ||| IN
MCAO  ||| S:1583 E:1588 ||| NNP
rats ||| S:1588 E:1592 ||| NNS
.  ||| S:1592 E:1594 ||| .
These  ||| S:1594 E:1600 ||| DT
findings  ||| S:1600 E:1609 ||| JJ
offer  ||| S:1609 E:1615 ||| NN
evidence  ||| S:1615 E:1624 ||| NN
for  ||| S:1624 E:1628 ||| IN
the  ||| S:1628 E:1632 ||| DT
first  ||| S:1632 E:1638 ||| JJ
time  ||| S:1638 E:1643 ||| NN
that  ||| S:1643 E:1648 ||| IN
BYHWD  ||| S:1648 E:1654 ||| NNP
may  ||| S:1654 E:1658 ||| MD
exert  ||| S:1658 E:1664 ||| VB
its  ||| S:1664 E:1668 ||| PRP$
neuroprotective  ||| S:1668 E:1684 ||| JJ
effects  ||| S:1684 E:1692 ||| NNS
partially  ||| S:1692 E:1702 ||| RB
by  ||| S:1702 E:1705 ||| IN
promotion  ||| S:1705 E:1715 ||| NN
of  ||| S:1715 E:1718 ||| IN
NPCs  ||| S:1718 E:1723 ||| JJ
migration  ||| S:1723 E:1733 ||| NN
to  ||| S:1733 E:1736 ||| TO
ischemic  ||| S:1736 E:1745 ||| VB
brain  ||| S:1745 E:1751 ||| NN
areas ||| S:1751 E:1756 ||| NNS
.  ||| S:1756 E:1758 ||| .
